| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expense) | 62,984 | 1,711 | ||
| Net loss | -1,781,255 | -2,662,193 | ||
| Net loss per common share - basic (in dollars per share) | -0.14 | -0.26 | ||
| Net loss per common share - diluted (in dollars per share) | -0.14 | -0.26 | ||
| Weighted average common shares outstanding - basic (in shares) | 12,575,983 | 10,369,127 | ||
| Weighted average common shares outstanding - diluted (in shares) | 12,575,983 | 10,369,127 | ||
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)